Content area
Abstract
Through the Consulting Labs organized by Professor Constança Casquinho of Nova School of Business and Economics, we were given the opportunity to write our Master’s Thesis about a real project at Instituto Português de Oncologia de Lisboa Francisco Gentil. The goal of this project was to write a Business Plan that would show the economic viability of the implementation and expansion of Pharmaceutical Consultations at IPO’s Pharmaceutical Ambulatory Care Unit. As a result, the project was written at this institution through the collaboration of Management and Finance students and with the constant support of professional Pharmaceutical staff.
IPO LFG:Founded in 29th of December 1923, IPO was created due to a need to investigate all aspects related to Cancer at a specialized institute, as well as to support patients with cancer-related problems.
Throughout the course of its history, IPO has always stood at the top of national standards by fulfilling its mission, with a multidisciplinary approach that follows the best clinical practices available, with the end goal of satisfying the needs of patients from the moment of diagnosis until the end of every course of treatment required.
Deliverables: The greatest challenges related to the project developed in the last 3 months can be split into two: 1. Verify if there is economic viability that explains the realization of Pharmaceutical Consultations and define the characteristics which optimize the model. 2. Define their future expansion path taking into consideration the pilot project.
Taking this into consideration, the project’s deliverables can be summed into the following topics: 1. An analysis of the pilot project, with the goal of underlining its economical benefits, while also considering the clinical gains delivered to the patients. 2. A methodology (described in detail in Annex 1) which makes it possible to assess, in a systematic way, the benefits previously described when considering expanding the Pharmaceutical Consultations to new drugs, which takes the form of an excel document and an instruction manual. 3. A proposal for criteria to expand the Pharmaceutical Consultation in the short and long term, as well as guidelines to mitigate future stakeholder risks which can arise in the expansion of the P.C.